NNVC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NanoViricides, Inc. (NNVC) is not a strong buy at this time for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst ratings and its innovative pharmaceutical focus, the lack of significant financial growth, neutral trading sentiment, and absence of positive technical signals suggest waiting for more favorable conditions or clearer catalysts.
The MACD is slightly positive at 0.0138, indicating mild bullish momentum, but it is contracting. RSI is neutral at 46.152, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. Key support is at 0.948, and resistance is at 1.057.
Analyst James Molloy initiated coverage with a Buy rating and a $6 price target, citing significant potential if NV-387 performs well in Phase 2 trials. The company specializes in innovative treatments for viral infections, which could be a high-growth area.
No recent news or significant trading trends from hedge funds or insiders. Financials show no revenue growth, a net income loss of -$2.22M, and a declining EPS (-21.43% YoY). Congress trading data is absent, and there are no strong technical or proprietary trading signals.
In Q2 2026, revenue remained at $0 with no YoY growth. Net income improved slightly (-9.53% YoY), but EPS dropped by 21.43% YoY to -0.11. Gross margin remains at 0, indicating no profitability.
Alliance Global analyst James Molloy initiated coverage with a Buy rating and a $6 price target, highlighting significant potential if NV-387 performs well in upcoming trials.
